{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:05:48Z","timestamp":1779897948585,"version":"3.53.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bvth.2026.100142","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:09:57Z","timestamp":1770116997000},"page":"100142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study"],"prefix":"10.1016","volume":"3","author":[{"given":"Shruti","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Nagalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kolodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola","family":"Oladapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Bernheisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-142X","authenticated-orcid":false,"given":"Elyse","family":"Swallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8576-8614","authenticated-orcid":false,"given":"Alexandra","family":"Greatsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Ormenaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7151-1065","authenticated-orcid":false,"given":"Sinia","family":"Sareen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Nicolas","family":"Ruiz Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vredenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Yair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bvth.2026.100142_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040789","article-title":"Primary immune thrombocytopenia: novel insights into pathophysiology and disease management","volume":"10","author":"Singh","year":"2021","journal-title":"J Clin Med"},{"issue":"23","key":"10.1016\/j.bvth.2026.100142_bib2","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.bvth.2026.100142_bib3","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bvth.2026.100142_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.27080","article-title":"Avatrombopag for adults with early versus chronic immune thrombocytopenia","volume":"99","author":"Virk","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bvth.2026.100142_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.bvth.2026.100142_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.bvth.2026.100142_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231179856","article-title":"Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study","volume":"14","author":"Oladapo","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.bvth.2026.100142_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bvth.2026.100142_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2195016","article-title":"Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia","volume":"34","author":"Jain","year":"2023","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.bvth.2026.100142_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bvth.2026.100142_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjh.19975","article-title":"Avatrombopag in adults with immune thrombocytopenia: a multicentre real-life observational study in Madrid, Spain (AVAMAD study)","volume":"206","author":"Pascual-Izquierdo","year":"2025","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bvth.2026.100142_bib15","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/ajh.27498","article-title":"Avatrombopag in immune thrombocytopenia: a real-world study of the Spanish ITP Group (GEPTI)","volume":"99","author":"Pascual-Izquierdo","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.bvth.2026.100142_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100134","article-title":"Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia","volume":"7","author":"Al-Samkari","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.bvth.2026.100142_bib17","series-title":"A European retrospective study to describe real-world outcomes, treatment patterns and resource use in patients with primary immune thrombocytopenia (ITP) treated with avatrombopag: interim results","author":"Francesco Zaja","year":"2024"},{"key":"10.1016\/j.bvth.2026.100142_bib18","series-title":"Platelet response to avatrombopag among patients with primary immune thrombocytopenia who switched from eltrombopag or romiplostim: the REAL-AVA 2.0 real-world study","author":"Shruti","year":"2025"},{"issue":"11","key":"10.1016\/j.bvth.2026.100142_bib19","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2024015635","article-title":"Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA","volume":"9","author":"Tarantino","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:21:06Z","timestamp":1779895266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950327226000070"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100142","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100142"}}